When genes are expressed - turned on, off, up or down - at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By creating medicines to control the expression of genes, we aim to make a profound difference in the lives of patients and their families. We are advancing a growing pipeline of investigational gene control medicines for diseases that have largely eluded other genomics-based approaches. Our current focus is on cancer and genetic diseases.
| Program | Indication | Discovery | Preclinical | Early Clinical | Mid-Stage Clinical | Pivotal | Commercial Rights |
|---|---|---|---|---|---|---|---|
SY-1425 (RARα agonist) |
SY-1425 (RARα agonist)
Frontline AML (combination with azacitidine) |
Discovery Phase complete
|
Preclinical Phase complete
|
Early Clinical Phase complete
|
Mid-Stage Clinical Phase in progress
|
Pivotal Phase not started
Syros (North America & Europe)
|
Syros (North America & Europe) |
|
SY-1425 (RARα agonist)
Relapsed or refractory AML (combination with azacitidine)* |
Discovery Phase complete
|
Preclinical Phase complete
|
Early Clinical Phase complete
|
Mid-Stage Clinical Phase in progress
|
Pivotal Phase not started
Syros (North America & Europe)
|
||
SY-1365 (CDK7 inhibitor) |
SY-1365 (CDK7 inhibitor)
Relapsed ovarian cancer, 3+ prior lines (single agent) |
Discovery Phase complete
|
Preclinical Phase complete
|
Early Clinical Phase in progress
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
|
SY-1365 (CDK7 inhibitor)
Relapsed ovarian cancer, 1+ prior lines (combination with carboplatin) |
Discovery Phase complete
|
Preclinical Phase complete
|
Early Clinical Phase in progress
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
||
|
SY-1365 (CDK7 inhibitor)
Recurrent ovarian clear cell cancer (single agent) |
Discovery Phase complete
|
Preclinical Phase complete
|
Early Clinical Phase in progress
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
||
|
SY-1365 (CDK7 inhibitor)
HR+ metastatic breast cancer (combination with fulvestrant) |
Discovery Phase complete
|
Preclinical Phase complete
|
Early Clinical Phase in progress
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
||
SY-5609 (Oral CDK7 inhibitor) |
SY-5609 (Oral CDK7 inhibitor)
Cancer |
Discovery Phase complete
|
Preclinical Phase in progress
|
Early Clinical Phase not started
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
CDK12/13 Inhibitor |
CDK12/13 Inhibitor
Cancer |
Discovery Phase complete
|
Preclinical Phase in progress
|
Early Clinical Phase not started
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
Program 5 |
Program 5
Immuno-oncology |
Discovery Phase complete
|
Preclinical Phase in progress
|
Early Clinical Phase not started
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
Discovery |
Discovery
Cancer/Immuno-oncology |
Discovery Phase in progress
|
Preclinical Phase not started
|
Early Clinical Phase not started
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
|
Discovery
Sickle Cell Disease |
Discovery Phase in progress
|
Preclinical Phase not started
|
Early Clinical Phase not started
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
||
Discovery |
Discovery
Myeloproliferative neoplasms |
Discovery Phase in progress
|
Preclinical Phase not started
|
Early Clinical Phase not started
|
Mid-Stage Clinical Phase not started
|
Pivotal Phase not started
Incyte (Global)
|
Incyte (Global) |
*Expected to begin in Q3 2019
Dan AML Patient
SY-1425
Our lead drug candidate, SY-1425, is a first-in-class selective retinoid acid receptor alpha (RARα) agonist in a Phase 2 clinical trial in genomically defined subsets of patients with acute myeloid leukemia.
View Program
Anne Ovarian Cancer Survivor
SY-1365
Our second most advanced program, SY-1365, is a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor in a Phase 1 clinical trial in patients with ovarian and breast cancers.
View Program